FBXO22 and hepatocellular carcinoma: Overexpression of FBXO22 was detected in 61.8% (68/110) of HCC patients and was significantly correlated with serum AFP (p = 0.003), tumor size (p = 0.019), and vascular invasion (p = 0.031).